Concepedia

H. I. Scher

HI

Statistics

Publications

2

Citations

1.5K

H-Index

2

Active since

2011

Affiliations

Sidney Kimmel Comprehensive Cancer Center(Current)

H. I. Scher is an author at Sidney Kimmel Comprehensive Cancer Center specializing in oncology, cancer therapeutics, and urology.

Top concepts

Publications per year

2011–2014

2

Publications

2

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

, , +9

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

H. I. Scher, Gerhard Fischer Wolf‐Dieter Heller, A. Molina et al. · Journal of Clinical Oncology · 2011 · 23 citations

, , +18

Rows per page

1–2 of 2